explore -WSS

explore

author：fashion 2025-09-29 01:06:18 - browse：4526

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Hospitals use virtual reality to design more inclusive rooms for kids

hotspot

WSS

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Regeneron agrees to White House price limits on anti

What to make of Biden’s latest efforts on cancer research

Wegovy cuts risk of cardiovascular events by 20%, study finds

Former Georgia lieutenant governor says he received grand jury subpoena

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Jerome Adams on the need for new antivirals for Covid

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Continuity nursing helped my family in our darkest PICU moments

FDA approves updated Covid vaccines

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

WATCH: Why do bright lights make us see spots?

Novavax promises a turnaround & Lilly roils the obesity market

FDA panel endorses Alnylam’s heart drug — after picking it apart

In Memoriam: Notable people who died in 2023

Hospitals consider fixing cancer drug shortages on their own

Wikipedia

The painfully weak evidence on taking collagen to treat arthritis

Popular nasal decongestant doesn't actually relieve congestion

Sage's campaign to raise awareness of postpartum depression hits a nerve

FDA proposes changes to key medical devices approval pathway

Travel bans should be based on evidence, not politics or fear

WATCH: Why do bright lights make us see spots?

hotspot

focus

hotspot

explore